Indolicidin

Scientific Overview

Indolicidin is a 13-aa tryptophan-rich cathelicidin originally isolated from bovine neutrophils (Selsted et al., 1992). It displays broad-spectrum activity against bacteria, fungi, and HIV in vitro via membrane permeabilization and intracellular targets. Hemolytic toxicity has limited systemic development; analogs (e.g. omiganan) reached topical Phase 3 trials.

Citations (4)

1. Mode of action of the antimicrobial peptide indolicidinPubMed
2. Design of novel indolicidin-derived antimicrobial peptides with enhanced cell specificity and potent anti-inflammatory activityPubMed
3. Structure and mechanism of action of an indolicidin peptide derivative with improved activity against gram-positive bacteriaPubMed
4. Mechanisms of antimicrobial peptide action: studies of indolicidin assembly at model membrane interfaces by in situ atomic force microscopyPubMed

Dosages listed are common research protocols found in peer-reviewed literature and clinical trials. Individual results and requirements may vary significantly in a research context.

Key Research Benefits

• Broad antimicrobial activity
• Active against multidrug-resistant strains (research)
• Membrane-disruption mechanism

Potential Side Effects

Labs to monitor

Educational context only, not a testing mandate. Any bloodwork decisions belong with your clinician.

• No validated compound-specific markers: No standard bloodwork is established for this compound; general safety labs (CBC, comprehensive metabolic panel) are reasonable if used under medical supervision.